Conferences

With preclinical/clinical transition being the largest failure risk in CNS therapeutics development, join us at HubXchange’s CNS Therapeutics Europe 2021 roundtable meeting, where senior drug developers from pharma and biotech share experiences and discuss the future research landscape. Jack Prenderville, Head of Transpharmation Ireland, will be presenting a poster on our latest neuroinflammation studies. Join him between 3.10 – 3.40pm CET, December 2nd, under preclinical discussion.

For more information on this event: https://www.hub-xchange.com/xchanges/

The Society for Neuroscience will hold Neuroscience 2021 as a fully virtual experience, eliminating all in-person options that had been planned for McCormick Place in Chicago, Illinois. Neuroscience 2021 will take place online November 8-11, 2021, with Preview Days taking place November 3-7, which allow attendees to preview posters as well as full symposia and minisymposia talks prior to the official meeting dates. Transpharmation has nine posters prepared across a range of topical and popular preclinical areas which will be revealed to you from our booth 1818. We look forward to connecting with you.

All poster presentations from this annual conference are now available on our YouTube channel 

If you would like to discuss any of these in more detail with us please contact us . Thank you.

For more information on the event please visit: https://www.sfn.org/meetings/neuroscience-2021

Neurex is one of the most important European networks in the field of Neuroscience and this is their first online Neurex lab-companies Neuroforum, an event aimed at gathering all the protagonists of the Neuroscience R&D dynamics. Transpharmation will be hosting a booth during the event, please drop in to find out all about the preclinical therapeutic areas in which we can help with your studies.

For further information about this event: https://www.neurex.org/events/events-to-come/item/505-the-neurex-neuroforum

The annual ECNP Congress is Europe’s premier scientific meeting for disease-oriented brain research, annually attracting more than 5,000 psychiatrists, neuroscientists, neurologists and psychologists from around the world. Transpharmation will be presenting a poster on “Rapid-acting antidepressants in motivation: the effects of low-dose ketamine and the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) in the rat progressive ratio task” - To view our abstract please click here 

To view our presentation click here https://youtu.be/9j-BoWpEEvA 
For more information on this event: https://www.ecnp.eu/Congress2021/ECNPcongress

Cannabinoids and Psychedelics; Neuroscience Ireland Meeting 2021 - 9th-10th September 2021

The Neuroscience Ireland 2021 meeting will be held virtually on 9th and 10th September 2021.The programme features 2 poster sessions, 4 themed symposia, 3 Plenary lectures and the Tom Connor Distinguished Investigator Award Prize Lecture. Click here to view the full programme https://neuroscienceireland.com/category/neuroscience-ireland-meeting-2021/ Dr Jack Prenderville, Head of Transpharmation Ireland will be presenting on 10th September, at 11.00 BST, focussing on Cannabinoids and Psychedelics with a look at innovative approaches to therapeutics to improve human health, with particular attention on the cannabinoid system and psychedelics in mental health, multiple sclerosis and ocular inflammatory disease.

Please click here to view our presentation

The FENS Regional Meeting (25-27 August 2021) is jointly organised by the Polish Neuroscience Society and theThe FENS Regional Meeting (25-27 August 2021) is jointly organised by the Polish Neuroscience Society and theLithuanian Neuroscience Association and will take place as an online meeting. Head of Transpharmation Poland, EwaSokolowska, will be presenting recent work based on the following abstract, “The effect of the second generation ofantipsychotic risperidone on aggressive behaviour in male CD-1 mice” on each day of this meeting 1-2 pm CEST,(central European summer time). If you are unable to attend the conference and would like to view this work please click here

The ICRS is dedicated to scientific research in all fields of the cannabinoids, ranging from biochemical, chemical, and physiological studies.

Transpharmation has a poster 'Investigating NLRP3-inhibitory potential of CBD' on display at this symposium during the daily poster sessions. It will be made available to you in the publications page of this website after the event. In the meantime, please feel free to read the abstract here: View Abstract.

For the full poster presentation see our publication.

The ICNMD International Congress on Neuromuscular Diseases is organized on behalf of the Neuromuscular Disorders Applied Research Group of the World Federation of Neurology.

The aim of the ICNMD Congresses is to offer participants an updated view on neuromuscular disorders as well as networking opportunities to increase their international experience and collaborations. Given our involvement in the BIND-Horizon Grant we look forward to hearing about the latest developments in this area.

With preclinical – clinical transition being the largest failure risk in CNS therapeutics development, join us at hubXchange’s CNS Therapeutics East Coast Virtual roundtable meeting, where senior drug developers from pharma and biotech share experiences and discuss the future research landscape.

Join us at 13.00 EST to hear Transpharmation’s Scientific Lead Sandor Kantor present ‘Changes in Brain Oscillatory Activity Might Predict the Efficacy of Therapeutics in Neuropsychiatric Disorders’. His 30 minute slot will cover the following:

• Disrupted sleep and abnormal brain oscillations are common early features of many neuropsychiatric disorders. Since sleep and EEG abnormalities often precede the clinical onset of these diseases, their possible involvement in the pathophysiological process is considered
• Medications used for symptomatic treatment of neuropsychiatric disorders often affect sleep and brain oscillatory activity. Furthermore, altering brain oscillatory activity by non-pharmacological means can improve the symptoms of the diseases
• Thus, the potential mechanistic relationship between changes in brain oscillatory activity and the pathophysiological process in these disorders will be discussed alongside with potential novel therapeutic targets

Find details of our sleep/wake work here

For more information on the speaker faculty, topics of discussion and registration process, please visit
https://www.hub-xchange.com/cns-therapeutics-xchange-east-coast-2021/#anchor1

The 21st Annual Conference will provide insights into cutting edge drug discovery science, preclinical development trends and will explore novel pain drug targets and novel biomarkers, including how industry is working to overcome the challenges of opioid-based treatment.

Transpharmation will be hosting round table talks on both days. Inflammation Pain Lead Ana Pereira will be discussing Translational endpoints for Preclinical Pain at 1pm on 10th May, Neuropathic Pain Lead Daniel Cohn will be discussing Novel Pharmacological approach in Pain Therapy at 11.20am on 11th May. We are also hosting ‘meet the team’ sessions at 11.20am and 4.30pm on the 10th May and 1.35pm on the 11th May. We hope to see you there.

To view our presentation click here https://youtu.be/eqM1_l8-sEI

The Neuroimmunology Drug Development Summit is the industry’s definitive and unrivalled forum focused on pushing the frontiers of targeting neuroinflammation for CNS Indications. Transpharmation is proud to be an Event Partner at this meeting and is joining the 80+ neuroimmunology drug development experts to present a poster on our new neuroinflammation models; Evaluation of Human ex vivo and Rodent in vivo Models of Inflammation for CNS Anti-Inflammatory Drug Development, as well as to learn from those pioneering the field, network and build meaningful future partnerships. To discover more about our Neuroimmunology & Neuroinflammation capabilities, please get in touch with us via https://www.transpharmation.co.uk/contact 

To view the work that we presented click here https://youtu.be/NDnTk6y6h3M

Each year, the BNA Festivals aim to bring together multiple organisations from both academia and industry interested in brain research, creating a novel, multi-organisation forum featuring all areas of
fundamental research in neuroscience and psychology. At the BNA 2021, Transpharmation is looking forward to being a part of the meeting, with our Cognition Lead and Scientific Liaison, John Huxter, presenting a workshop on improving translation between industry and academia in neuroscience under the topic of "Pitfalls and prospects for cognitive assays in preclinical research". Please feel free to visit us at our booth to discuss the specific translational models.
For more information on the conference, please visit https://meetings.bna.org.uk/bna2021/programme_information/

The 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD™ 2021, will build on the well-earned reputation of the ground-breaking series of Alzheimer’s and Parkinson’s Diseases Conferences, which attract international medical and scientific professionals worldwide.

Transpharmation’s Scientists Caoimhe Tyndall and Teresa Burke will be presenting posters on the topics of “Glial-neuronal interaction prompted by recombinant fibrillar protein constructs of alpha-synuclein – an invitro characterisation” & “A53T alpha-synuclein promotes a rapid neurodegeneration and motor deficit following AAV vector mediated expression in the rat substantia nigra” respectively. Read our abstract papers here: Abstract Papers

Each year ASENT Annual meeting features sessions on emerging therapies in a wide variety of neurologic disease states from Parkinson’s Disease and Movement Disorders, Pain, Multiple Sclerosis, Epilepsy, and a variety of other neurodegenerative Disorders.

Transpharmation will be presenting posters on the topics of “Modulation of the p38 MAPK Pathway in Peripheral Blood Mononuclear Cells (PBMCs): Implications for screening novel anti-inflammatories in Alzheimer’s Disease (AD)” & “Establishment of a reversal learning assay in rats to investigate the effects of novel compounds on executive function.” To get more info on the topics of discussion and registration process please go to https://asent.org/

Transpharmation's EEG experts Dr. John Huxter and Dr. Sandor Kantor discussed how EEG can bridge the gap between basic research, preclinical drug discovery and human clinical trials at a virtual social (SO39) at the SfN Connectome on Tuesday 12th January at 9-10am EST (2-3pm GMT). This social stimulated discussion around what EEG measures offer the best hope for predicting clinical outcomes, probing strengths, weaknesses, and usage of measures like ASSR and MMN.

The first International Association for the Study of Pain, (IASP) virtual conference is live! If you haven’t registered, please use this link https://www.eventscribe.com/2020/IASP-Virtual-Series-on-Pain/ We are delighted to be taking part by being one of the event sponsors and hosting a booth to showcase our latest work on pain. There are networking rooms and a range of topical workshops to attend https://www.eventscribe.com/2020/IASP-Virtual-Series-on-Pain/agenda.asp?pfp=FullSchedule We look forward to seeing you there!